Highlights Synlogic, Inc.

Equities

SYBX

US87166L2097

Delayed Nasdaq Other stock markets 11:59:11 2024-04-29 am EDT			5-day change	1st Jan Change
1.879 ^USD	+0.49%		+2.13%	-51.19%

Mar. 21	Synlogic, Inc. Announces Board Changes	CI
Mar. 21	North American Morning Briefing : Investors -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Investors -2-	Mar. 21	DJ
Earnings Flash (SYBX) SYNLOGIC Reports Q4 Revenue $2.8M	Mar. 19	MT
Synlogic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Synlogic, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Synlogic Board Approves Poison Pill Defense After Unsolicited Accumulation of Shares	Feb. 20	MT
North American Morning Briefing : Stock Futures -2-	Feb. 12	DJ
Synlogic, Inc. Announces Decision to Discontinue Synpheny-3 Study	Feb. 08	CI
Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria	Feb. 02	CI
Synlogic Wins Air Force Research Lab Subcontract for Live Probiotic Development Support	Dec. 27	MT
Synlogic, Inc. Announces Contract with the Air Force Research Lab	Dec. 27	CI
Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000	Nov. 09	MT
Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration	Nov. 07	CI
Synlogic to Implement 1-for-15 Reverse Stock Split	23-09-28	MT
Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000	23-08-10	MT
Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Science 37's Metasite Selected by Synlogic for Virtual Clinical-Trial Platform for Potential Phenylketonuria Treatment	23-07-11	MT
Synlogic, Inc. Grants Fast Track Designation from FDA for Labafenogene Marselecobac for Treatment of Phenylketonuria	23-07-11	CI
Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria	23-06-05	CI
Earnings Flash (SYBX) SYNLOGIC Reports Q1 Revenue $174,000	23-05-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Synlogic, Inc.

Equities

SYBX

US87166L2097

Highlights

Filters